argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Analysts

argenx SE (NASDAQ:ARGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty-three ratings firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $630.42.

A number of analysts recently commented on ARGX shares. Robert W. Baird downgraded shares of argenx from an "outperform" rating to a "neutral" rating and boosted their price objective for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Evercore ISI boosted their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Wells Fargo & Company boosted their price objective on shares of argenx from $547.00 to $639.00 and gave the stock an "overweight" rating in a report on Friday, November 1st. Oppenheimer reissued an "outperform" rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Finally, Scotiabank upgraded shares of argenx from a "sector perform" rating to a "sector outperform" rating and lifted their target price for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th.

Hedge Funds Weigh In On argenx

Several institutional investors and hedge funds have recently bought and sold shares of ARGX. J.Safra Asset Management Corp grew its stake in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after buying an additional 59 shares during the period. Blue Trust Inc. boosted its stake in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after purchasing an additional 62 shares during the period. GAMMA Investing LLC boosted its stake in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares during the period. Cromwell Holdings LLC boosted its stake in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after purchasing an additional 66 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of argenx in the 2nd quarter valued at about $76,000. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Stock Performance

NASDAQ ARGX traded up $7.43 during trading on Thursday, reaching $614.59. The company's stock had a trading volume of 405,338 shares, compared to its average volume of 310,991. The firm has a market cap of $37.10 billion, a price-to-earnings ratio of -698.40 and a beta of 0.61. The business's fifty day moving average price is $562.49 and its 200-day moving average price is $493.62. argenx has a twelve month low of $327.73 and a twelve month high of $620.28.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the previous year, the firm earned ($1.25) earnings per share. As a group, sell-side analysts forecast that argenx will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.